Therapeutic Classification: antiplatelet agents
Pharmacologic Classification: platelet aggregation inhibitors
Absorption: 36% absorbed following oral administration.
Distribution: Well distributed to tissues.
Protein Binding: 99%.
Metabolism/Excretion: Mostly metabolized in the liver by the CYP3A4 isoenzyme, with some metabolism by the CYP3A5 isoenzyme) with conversion to an active metabolite (AR-C124910XX); excretion primarily via biliary secretion; <1% excreted unchanged or as active metabolite in urine.
Half-life: Ticagrelor: 7 hr; Active metabolite: 9 hr.
Contraindicated in:
Use Cautiously in:
CV: bradycardia, heart block.
Endo: gynecomastia.
Hemat: BLEEDING.
Resp: dyspnea, central sleep apnea, Cheyne-Stokes respiration.
Misc: (INCLUDING ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .
Drug-Drug:
Acute Coronary Syndrome or History of Myocardial Infarction
Coronary Artery Disease Without a History of Myocardial Infarction or Stroke
Acute Ischemic Stroke or Transient Ischemic Attack